key: cord-0935914-1m9jo0iu
authors: Chen, K.Y.; Krischuns, T.; Varga, L.Ortega; Harigua-Souiai, E.; Paisant, S.; Zettor, A.; Chiaravalli, J.; Delpal, A.; Courtney, D.; O'Brien, A.; Baker, S.C.; Decroly, E.; Isel, C.; Agou, F.; Jacob, Y.; Blondel, A.; Naffakh, N.
title: A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors
date: 2022-03-09
journal: Antiviral Res
DOI: 10.1016/j.antiviral.2022.105272
sha: 7fad84ff08de040cfdd1e76ba1c095970b440149
doc_id: 935914
cord_uid: 1m9jo0iu

Effective drugs against SARS-CoV-2 are urgently needed to treat severe cases of infection and for prophylactic use. The main viral protease (nsp5 or 3CLpro) represents an attractive and possibly broad-spectrum target for drug development as it is essential to the virus life cycle and highly conserved among betacoronaviruses. Sensitive and efficient high-throughput screening methods are key for drug discovery. Here we report the development of a gain-of-signal, highly sensitive cell-based luciferase assay to monitor SARS-CoV-2 nsp5 activity and show that it is suitable for the screening of compounds in a 384-well format. A benefit of miniaturisation and automation is that screening can be performed in parallel on a wild-type and a catalytically inactive nsp5, which improves the selectivity of the assay. We performed molecular docking-based screening on a set of 14,468 compounds from an in-house chemical database, selected 359 candidate nsp5 inhibitors and tested them experimentally. We identified two molecules which show anti-nsp5 activity, both in our cell-based assay and in vitro on purified nsp5 protein, and inhibit SARS-CoV-2 replication in A549-ACE2 cells with EC(50) values in the 4–8 μM range. The here described high-throughput-compatible assay will allow the screening of large-scale compound libraries for SARS-CoV-2 nsp5 inhibitors. Moreover, we provide evidence that this assay can be adapted to other coronaviruses and viruses which rely on a viral protease.

In January 2020, a novel human coronavirus named severe acute respiratory syndrome coronavirus 2 3 (SARS-CoV-2) was identified as the causative agent of the COVID-19 disease. SARS-CoV-2 has spread 4 globally, causing a pandemic that is still on-going and has to date infected over 408 million people and 5 caused over 5.8 million deaths worldwide (John Hopkins University, 2022) . Vaccines started to be 6 deployed early 2021 and more than 6.4 billion doses have been administered to date (John Hopkins et al., 2020; Rathnayake et al., 2020; Zhang et al., 2020; Zhu et al., 2020) . However, in vitro assays need 23 to be complemented with cell-based assays as they do not take into account compound membrane 24 permeability, toxicity and bioavailability in cells. Cell-based reporter assays that can be performed in a 25 Biosafety Level 1 (BSL1) setting have been developed (Froggatt et al., 2020; O'Brien et al., 2021a;  26 Rawson et al., 2021; Resnick et al., 2021; Rothan and Teoh, 2021) but their suitability for high-27 throughput screening has not been demonstrated. Here we report the development of a rapid and highly 28 sensitive cell-based luciferase assay to monitor SARS-CoV-2 nsp5 activity. We provide evidence that 29 the reporter assay is suitable for high-throughput automated screening of large libraries of compounds 30 and report the identification of two lead compounds that inhibit protease activity in our cell-based assay 31 and in vitro on purified nsp5 protein, and inhibit SARS-CoV-2 replication in cell culture. 32 33 J o u r n a l P r e -p r o o f 1 HEK-293T cells were seeded in 96-well white opaque plates (Greiner Bio-One, 3x10 4 cells per well) 2 one day before being transfected with 5 ng of the Rev-Nluc-CoV reporter plasmid and 95 ng of the 3 pcDNA3.1-nsp4-5-6 WT, pcDNA-3.1-nsp4-5-6 C145A, pLEX-nsp5 or an empty control pCI plasmid, 4 using polyethyleneimine (PEI-max, #24765-1 Polysciences Inc). To measure NS3/4A activity, 5 ng of 5 the Rev-Nluc-HCV reporter plasmid was co-transfected with 145 ng of the pCI-NS3/4A WT or pCI-6 NS3/4A S139A, using the same protocol. Nanoluciferase activity was measured at 24 or 48 hours post-7 transfection (hpt) using the Nano-Glo® Luciferase Assay System (#1120, Promega) and a Berthold 8 Centro XS3 luminometer (integration time 1s/well using the MikroWin® software). When indicated, 9 cells were treated at 8 hpt with increasing concentrations of the inhibitors GC376 (Sigma-Aldrich), 10 Calpain Inhibitor XII (Cayman Chemicals), Mpro 13b (Bio-Techne), Boceprevir (Sigma-Aldrich) and 11 PF-07321332 (MedChem Express) with a constant DMSO concentration of 0.1%, for ~14 h.

Nanoluciferase activity was measured at 24 hpt.

In the 384-well plate setting, ~10 7 HEK-293T cells were transfected in 50 cm 2 dishes with 1 μg of the 14 Rev-Nluc-CoV plasmid and 15 μg of the nsp4-5-6 WT or nsp4-5-6 C145A expression plasmids.

15 Increasing amounts of the tested compounds, corresponding to final concentrations of 0.1 to 50 µM with 16 a constant DMSO concentration of 0.5% were distributed in 384-well white opaque plates using an Echo 1 µg/mLDNAse I). After 3 cycles of sonication and clarification, the 6xHis-tagged protein was purified 2 by NTA affinity on cobalt beads, and the nsp5 protein was eluted in lysis buffer supplemented with 250 3 mM imidazole. The nsp5 protein was then concentrated on Vivaspin 20 centrifugal concentrators 10 4 kDa MWCO (GE Healthcare #VS2001), dialysed against the elution buffer in the absence of imidazole, 5 and stored at -80°C upon addition of 50% glycerol. CoV-2 specific primers targeting the N gene region (5'-TAATCAGACAAGGAACTGATTA-3' and 28 5'-CGAAGGTGTGACTTCCATG-3') and with the following cycling conditions: 55 °C for 10 min, 29 95 °C for 1 min, for 1 cycle, followed by 95 °C for 10 sec, 60 °C for 1 min, for 40 cycles in an Applied 30 Biosystems QuantStudio 6 thermocycler. The percentage of viral growth inhibition was calculated as 31 the ratio of the sample mean Ct to the positive control (remdesivir 1 µM) mean Ct, after subtracting the 32 negative control (DMSO 0.5 %) mean Ct. Cell viability assays were performed in drug-treated cells 33 using the CellTiter-Glo assay according to the manufacturer's instructions (Promega) and a Berthold

To develop a Nanoluciferase-based reporter for SARS-CoV-2 nsp5 activity, we built on our experience 4 in engineering a split Nanoluciferase for protein complementation assays (Choi et al., 2019) . We 5 designed a reverse-Nanoluciferase (Rev-Nluc-CoV, Figure 1A ) in which the two independent structural 6 Nanoluciferase domains corresponding to amino acids 2-66 and 66-171 are permuted and separated by 7 a flexible loop including the coronavirus nsp5 consensus cleavage site VRLQ/S (Kilianski et al., 2013).

As a control, a TEV protease cleavage site or a sequence corresponding to two BsmBI restriction sites 9 was inserted into the Rev-Nluc (Rev-Nluc-TEV and Rev-Nluc-control, respectively) . To determine the 10 efficiency of nsp5-mediated Rev-Nluc cleavage, the Rev-Nluc-CoV plasmid was co-transfected with a 11 plasmid encoding nsp4, nsp5 and the amino-terminal part of nsp6 (O'Brien et al., 2021a) . Previous 12 studies have shown that nsp5 is released upon autocatalytic processing of the coronavirus nsp4-5-6 13 polyprotein (Kilianski et al., 2013; Muramatsu et al., 2016; O'Brien et al., 2021a) . As a control, a 14 catalytically inactive nsp5 mutant (C145A) was used (Muramatsu et al., 2016) .

A luciferase signal was measured in cells co-transfected with the Rev-Nluc-CoV-2 and a control empty 16 plasmid, demonstrating that the permuted Nanoluciferase domains form an active enzyme. Compared 17 to the empty vector control, cells co-transfected with the SARS-CoV-2 nsp4-5-6 WT plasmid showed a 18 ~30-fold reduction in luciferase signal at 48 hpt, whereas Nanoluciferase signals in cells co-transfected 19 with the SARS-CoV-2 nsp4-5-6 C145A remained unchanged ( Figure 1B , white bars, and 20 Supplemental Figure 1 ). When the Rev-Nluc-TEV and Rev-Nluc-control plasmids were used instead 21 of the Rev-Nluc-CoV reporter plasmid, cells co-transfected with nsp4-5-6 WT showed a ~5-fold 22 decrease in luciferase signal ( Figure 1B , light and dark grey bars, respectively). These data indicate that 23 upon autocatalytic processing of the SARS-CoV-2 nsp4-5-6 polyprotein, the released nsp5 restricts the 24 production of an active Nanoluciferase, and it does so through two distinct mechanisms: 1) cleavage of 25 the canonical nsp5 site VRLQ/S in the Rev-Nluc and 2) reduction of Nanoluciferase activity 26 independent of the canonical cleavage site, possibly caused by nsp5-mediated cleavage of Rev-Nluc at 27 other sites or indirectly by cleavage of cellular proteins. The cleavage of the reporter is strictly dependent 28 on the protease activity of nsp5, as demonstrated by the nsp5 C145A mutant. When nsp5 was expressed 29 alone instead of the nsp4-5-6 polyprotein, the observed fold-changes were lower ( Figure 1B) .

An orthogonal assay was used to confirm that the reduction in luciferase signal was due to nsp5-31 mediated cleavage of the reporter. The Rev-Nluc-CoV reporter was fused to the 3xFLAG tag at its N-32 terminal end and cleavage was assessed by western-blot using an anti-FLAG antibody. As shown in 33 Supplemental Figure 2 , the full-length Rev-Nluc-CoV protein could no longer be detected upon co-(compared to 30 kD for the uncleaved Rev-Nluc) could not be detected either, suggesting that it is 1 degraded upon cleavage.

In an attempt to optimize the Rev-Nluc reporter, we replaced the initial coronavirus nsp5 consensus 5 VRLQ/S cleavage site by the VARLQ/SG sequence that was identified as an optimal SARS-CoV nsp5 6 cleavage site (Chuck et al., 2011) , or by three nsp5 cleavage sites in the SARS-CoV-2 ORF1a at the 7 nsp4-5 (SAVLQ/SG), nsp5-6 (GVTFQ/SA) and nsp9-10 (TVRLQ/AG) junctions. With all reporter 8 plasmids, a decrease in luciferase signal was measured in cells expressing SARS-CoV-2 nsp4-5-6 WT 9 ( Figure 1C , white bars) compared to the empty vector, but not in cells expressing the mutant SARS-10 CoV-2 nsp4-5-6 C145A ( Figure 1C , dark grey bars). The highest fold change was observed with the 11 Rev-Nluc-CoV plasmid (VRLQ/S), which was used in the following experiments in combination with 12 SARS-CoV-2 nsp4-5-6 WT or C145A.

The fold-change in Nanoluciferase signal measured between the WT and C145A mutant is dependent 16 on nsp5 enzymatic activity and can therefore be used as a proxy for in vivo nsp5 activity. To investigate 17 whether the Rev-Nluc reporter could be used to screen for inhibitors of nsp5, we tested the commercially 18 available GC376 compound that was reported to inhibit SARS-CoV-2 nsp5 activity in vitro (Fu et al., 19 2020; Ma et al., 2021) as well as in cell-based assays (Froggatt et al., 2020; Rawson et al., 2021) and to 20 inhibit SARS-CoV-2 replication in Vero cells (Hung et al., 2020) . GC376 dose-dependently reduced 21 nsp5 activity, as seen by a gradual increase of Nanoluciferase activity measured in the presence of 22 SARS-CoV-2 nsp4-5-6 WT ( Figure 1D , open symbols), while the luciferase signal measured in the 23 presence of catalytically inactive mutant remained unchanged ( Figure 1D , closed symbols). Full 24 inhibition of nsp5 was achieved at 10 µM GC376 and the estimated IC50 was in the micromolar range, 25 in agreement with previous findings in cell-based assays (Froggatt et al., 2020; Iketani et al., 2021;  26 Vuong et al., 2020) . The inhibitory effects of Calpain Inhibitor XII and Boceprevir as determined by the 27 Rev-Nluc assay were lower compared to GC376 (Figures 1E and 1F) 

We asked whether the Rev-Nluc-CoV reporter can be used to monitor the activity of nsp5 proteins from 32 distantly related coronaviruses. To this end, the Rev-Nluc-CoV plasmid was co-transfected with nsp5 33 expression vectors derived from SARS-CoV-2 (Betacoronavirus), the human seasonal coronavirus 34 229E (hCoV-229E, Alphacoronavirus) or the avian infectious bronchitis virus (IBV, 1 with data obtained with an nsp5 FlipGFP reporter (Froggatt et al., 2020) , and show that the Rev-Nluc 2 assay can be adapted to other coronaviruses. 3 Next, we asked whether the Rev-Nluc reporter could be used to monitor the activity of a distinct class 4 of proteases, the hepatitis C virus (HCV) NS3/4A serine protease. The Rev-Nluc-HCV reporter plasmid, 5 in which the two Nanoluciferase subdomains are linked by the NS5A/5B cleavage site EDVVCCSMSY, 6 was co-transfected with an expression vector for NS3/4A protease. Cells co-transfected with the NS3/4A 7 plasmid showed a ~20-fold reduction in luciferase signal at 48 hpt, whereas luciferase signals in cells 8 co-transfected with the catalytically inactive S139A mutant (Bartenschlager et al., 1993) (Rarey et al., 1996) , as the combination of these four docking schemes gave the best 5 results for crossdocking on the non-covalent crystallographic complexes. Molecules which could not be 6 docked because they had unusual atoms, had too many rotatable bonds, or could not fit for other reasons 7 were discarded. Out of the 14,468 compounds, 13,781 could be docked at least once for one of their 8 ~60,000 tautomers/conformers. With up to 10 poses recorded, this led to ~2,400,000 poses. For each 9 docking pose, a pharmacophoric score (named PHARMscore) was calculated as described in the 10 Methods section. Noticeably, comparison of the docking poses of FlexX and Smina on PDB 5RH8 11 showed better PHARMscore for FlexX. Correlations between the PHARM scores and rescoring values 12 were significant for the selected molecules (from 0 to 58%) ("Whole selection" in the Supplemental 13 Table 1 ). The correlation was higher for the best rescored poses than for the best PHARM poses, 14 suggesting that the rescoring considers the molecular contacts used to calculate the PHARMscores and 15 is more exhaustive. Table 1 and Table 1 ). A second filtering of the ~2,400,000 poses was performed based 32 on features frequently observed both in available crystallographic complexes (Dai et al., 2020; Fu et al., 33 2020; Gunther et al., 2021; Jin et al., 2020; Lockbaum et al., 2021; Ma et al., 2020; Sacco et al., 2020;  34 Su et al., 2020; Zhang et al., 2020) and in the poses of the in silico Selection #1 (namely hydrogen bonds 35 to residues 163 and 166 and pyridine, acetamide/urea moieties) and geometric/positional similarity to crystal complexes. The 1354 filtered poses, representing 1142 unique molecules, were visually 1 inspected to select 20 additional molecules (named in silico Selection #2). In total, 359 molecules 2 (Selection #1 and #2) were selected for experimental testing.

Screening of candidate nsp5 inhibitors 5 We applied the 384-well Rev-Nluc-assay pipeline to test the 339 candidate nsp5 inhibitors 6 corresponding to the in silico Selection #1. In parallel, we also tested a commercial (TargetMol) library 7 of 161 small molecules with potential anti-nsp5 activity as predicted by molecular docking. In a primary Table 1 , compounds #1 to #24).

To assess the specificity of nsp5 inhibition and potential cell toxicity, the 24 primary hit compounds 16 were tested at a final concentration of 10 µM in cells transfected with either SARS-CoV-2 nsp4-5-6 WT 17 or C145A. Compounds that led to an increased (> 120%) or decreased (< 80%) luciferase signal in 18 SARS-CoV-2 nsp4-5-6 C145A-transfected cells were discarded. The 5 remaining compounds (# 5, 9, 19 11, 22 and 24, highlighted in blue in Table 1 ) induced a moderate to strong increase in luciferase signal 20 with nsp5-WT, consistent with the primary screening data. The strongest increase (39% compared to 21 the 50 µM GC376 control) was observed with compound #5. The twenty in silico Selection #2 22 compounds were tested in the same conditions as the 24 primary hits and assessed using the same 23 criteria, which led to the selection of two additional compounds (#35 and #39 in Table 1 ).

Dose-response curves were generated for the 7 secondary hit compounds on cells expressing either nsp5 25 WT or the nsp5 C145A mutant. Compound #9 (Pacritinib) showed a dose-response curve with an 26 irregular pattern (Supp Figure 7A ) and was not further considerd. The IC50 was estimated > 50 µM for 27 compounds #11 (Fr-PPIChem-33-E11_10265) and #22 (Fr-PPIChem-08-N15_02513) (Supp Figure The ability of compounds #5, #24, #35 and #39 (whose structure is shown in Figure 5A ) to inhibit 10 SARS-CoV-2 replication was evaluated in a multicycle replication assay on A549-ACE2 cells, followed compounds into more active derivatives, or from a dual inhibition of nsp5 together with other viral or 20 cellular protein(s). In summary, the screening of 500 potential SARS-CoV-2 nsp5 inhibitors by the here 21 described assay led to the identification of 2 potential lead compounds (#24, #39) with low cell toxicity 22 up to 50 µM (SI > 7 and > 10, respectively) and a higher antiviral activity against SARS-CoV-2 23 replication as compared to the reference compound GC376, which demonstrates the potential of the 1 We developed and validated a sensitive, high-throughput cell-based assay to monitor SARS-CoV-2 nsp5 2 proteolytic activity. We used this cell-based assay to screen a library of 339 candidate molecules for 3 their ability to inhibit SARS-CoV-2 nsp5 activity, and identified two novel lead compounds. This was 4 achieved by engineering a Reverse-Nanoluciferase (Rev-Nluc) reporter in which two Nanoluciferase 5 domains are permuted and linked together by an nsp5 cleavage site. Co-expression with the SARS-CoV-6 2 nsp4-5-6 polyprotein results in cleavage of the reporter and thereby a significant reduction in luciferase 7 activity. The addition of a specific nsp5 inhibitor results in a dose-dependent restoration in luciferase 8 activity. A ~30-fold increase in luciferase activity is observed in the presence of 50 µM GC376, similar 9 to the level of luciferase activity observed when a control inactive nsp4-5-6 polyprotein is co-expressed 10 with the reporter instead of the wild-type nsp4-5-6. The strengths of the Rev-Nluc-based assay lie in the 11 following: i) it is a gain-of-signal assay and therefore excludes compounds that are cytotoxic or interfere 12 negatively with the Nanoluciferase read-out; ii) it is rapid and convenient due to the glow-type signal of 13 the Nanoluciferase; iii) it is amenable to miniaturisation due to the very bright luminescence signal 14 produced by the Nanoluciferase; and iv) as a consequence of its rapidity and miniaturisation it can be 15 run in parallel on a wild-type and a catalytically inactive nsp5, which allows for the identification of 16 compounds that restore the luciferase activity in both conditions and to discard them as false-positives.

Unlike previously described SARS-CoV-2 nsp5 reporter assays, we provide evidence that our Rev-18 Nluc-based assay is scalable for high-throughput screens in a 384-well format.

The first cell-based assays for SARS-CoV-2 nsp5 to be described were loss-of-signal assays based on a 

We screened a total of 520 molecules with potential anti-nsp5 activity as predicted by molecular 6 docking: 359 molecules from the in silico screening approach and 161 molecules from a commercial 7 targeted library. A primary screen, performed at a single concentration on the wild-type nsp5 protein 8 only, identified 24 hits. The subsequent secondary screen, performed at a single concentration on the 9 wild-type and catalytically inactive nsp5 proteins in parallel, led us to discard most of the primary hits 10 as being toxic or false-positives and to select only 7 molecules, all coming from the in silico screening 11 approach. Five out of these 7 selected molecules were found to inhibit purified nsp5 protease activity in 

Merimepodib was later found to have antiviral activity against several DNA and RNA viruses including 25 HCV, Zika, Ebola and FMDV viruses (Li et al., 2019; Marcellin et al., 2007; Markland et al., 2000;  26 Tong et al., 2018) . In the early phase of the COVID-19 pandemic, oral merimepodib was investigated 27 in combination with intravenous remdesivir administration in a phase 2 clinical trial as a potential 28 treatment for severe COVID-19. The trial sponsor announced in October 2020 that the trial was 29 discontinued because it was unlikely that it would meet its primary safety endpoints (ViralClear, 2020).

Intriguingly, we found that merimepodib inhibits SARS-CoV-2 replication on A549-ACE2 cells with 31 an EC50 of 21 µM and inhibits SARS-CoV-2 nsp5 protease activity in 293T cells with an IC50 < 50 µM, 32 whereas it does not efficiently inhibit nsp5 protease activity in vitro. Merimepodib is unlikely to be a 33 false-positive in the Rev-Nluc assay as it has a much stronger effect in the presence of the wild-type 34 nsp5 compared to the catalytically inactive nsp5. Our observations are more likely explained by a 35 different conformation of nsp5 and a higher accessibility of merimepodib binding site in the cellular 36 J o u r n a l P r e -p r o o f context, or by an indirect mechanism of inhibition. Therefore, our data suggest a particular and 1 unexpected mode of action of this compound against the SARS-CoV-2 virus. Merimepodib is thought 2 to exert its broad antiviral activity by reducing the pool of intracellular guanine nucleotides and thereby 3 impairing RNA and DNA synthesis. The question whether merimepodib can inhibit other viral cysteine-4 dependent proteases and to what extent this anti-protease activity contributes to its antiviral activity 5 deserves to be further explored.

We also identified two compounds (#24 and #39 in Table 1 and 

S., Gong, F., Liu, Y., Wei, Y., Dong, C., Zhou, F., Gu, X., Xu, J., Liu, Z., Zhang, Y., Li, H., Shang, L., Wang, 33 K., Li, K., Zhou, X., Dong, X., Qu, Z., Lu, S., Hu, X., Ruan, S., Luo, S., Wu, J., Peng, L., Cheng, F., Pan, L., 34 Zou, J., Jia, C., Wang, J., Liu, X., Wang, S., Wu, X., Ge, Q., He, J., Zhan, H., Qiu, F., Guo, L., Huang, C., A. Luciferase signal measured at 48 hpt in HEK-293T cells co-transfected with a Rev-Nluc reporter 23 (with a CoV or control linker sequence) and nsp5 (derived from SARS-CoV-2, hCoV-229E, or IBV).

The graph shows the RLU fold-reduction compared to cells transfected with an empty control plasmid 25 (mean ± SD of three independent experiments performed in technical triplicates). The amino acid 26 sequence identity compared to SARS-CoV-2 nsp5 is indicated below the graph.

B. Luciferase signal measured at 48 hpt in HEK-293T cells co-transfected with a Rev-Nluc reporter 28 (with an HCV-NS5A/5B, a CoV cleavage site, or a control linker sequence) and HCV-NS3/4A protease 29 (WT or S139A) or SARS-CoV-2 nsp4-5-6. The graph shows the RLU fold-reduction compared to cells 30 transfected with an empty control plasmid instead of an NS3/4A or nsp4-5-6 plasmid (mean ± SD of 31 three independent experiments performed in technical triplicates). 

The Rev-Nluc assay was performed as described in the methods section throughout a series of ten 384-31 well plates. SARS-CoV-2-nsp5 inhibition was assessed in the presence of GC376 at final concentrations 32 of 10, 1 or 0.1 µM (16 wells for each condition in each plate). As described in Figure Sigma) or GAPDH (MA5-15738, Invitrogen), and revealed with HRP-linked secondary antibodies 6 (Jackson ImmunoResearch) using ECL2 substrate (Pierce). The chemiluminescence signals were 7 acquired with the ChemiDoc imaging system and the images were analyzed with ImageLab (Bio-Rad). for other structures, which when combined provided a larger diversity in the union of successful 20 redocked molecules. We chose the weighting scheme taking chemical diversity into account that is given 21 in the Supplemental Table 2 .

The best combination with one other structure (5R7Z in addition to 7JU8) gave a score of 8 (max score 23 29) and successful docking for 12 molecules. The best combination of 3 structures gave a score of 12.1, 24 but only 16 ligands so we kept the second combination (7JU7, 5R7Z, 5RH8), with a score of 11.4, but 25 18 ligands. It also comprised 5RH8, which gave the best results with FlexX, allowing to diversify the 26 screening with FlexX, while providing a basis for comparison between the two programs. 

New substructure filters for removal of pan assay interference compounds A sdf format file containing the "2D" molecule information was exported from the Collaborative Drug 11 Discovery program (www.collaborativedrug.com) used to manage the in-house Pasteur chemical 12 library. This library includes the Fr-PPI-Chem library of 10,314 putative protein-protein interaction 13 (PPI) inhibitors (Bosc et al., 2020). The remaining 4,154 compounds (including FDA approved drugs, 14 natural compounds, anti-cancer and anti-viral candidates

The chemical diversity of the library is

A "3D" sdf version was prepared for docking using an in-house automated pipeline performing: 18 Chemical standardization and curation (ChEMBL protocols

Selection of species populating more than 21 25% or, if none, species that are present at more than 75% of the most frequent one, or at least the three Structure selection for virtual screening

Analysis of the available non-covalent complex structures revealed very close conformations

Structure 7JU7 obtained in complex with masitinib is one of 16 those outliers (1.84 Å of the first cluster centroid)